97260 ⎘
Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
METHOD FOR PREPARING HER2 NANOBODY AND CONJUGATE, AND USE THEREOF
#2CHIMERIC ANTIGEN RECEPTORS TARGETING INTERLEUKIN 13 RECEPTOR SUBUNIT ALPHA 2 AND METHODS OF USE THEREOF
#3ALBUMIN BINDING PROTEINS AND METHODS OF USE
#4ANTI-UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#5SMALL SHEDDING BLOCKING AGENTS
#6IMMUNOGLOBULIN VARIABLE DOMAINS
#7CD8 BINDING AGENTS
#8CD3-TARGETING ANTIBODY AND USE THEREOF
#9CLEC9A BINDING AGENTS
#10VHH ANTIBODIES AND USES THEREOF
#11MODULATION OF DENDRITIC CELL LINEAGES
#12ANTIBODY AND CHIMERIC ANTIGEN RECEPTORS TARGETING GCC AND METHODS OF USE THEREOF
#13TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
#14ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#15MONOVALENT ANTI-PROPERDIN ANTIBODIES AND ANTIBODY FRAGMENTS
#16SINGLE DOMAIN ANTIBODIES TARGETING HPV E6/E7 ONCOGENIC PEPTIDE/MHC COMPLEXES
#17CD8 BINDING AGENTS
#18ALBUMIN BINDING PROTEINS AND METHODS OF USE
#19ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
#20ANTIBODIES TO CD70
#21ALBUMIN BINDING PROTEINS AND METHODS OF USE
#22NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT
#23COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
#24POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS
#25COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
#26IL10RB BINDING MOLECULES AND ENCODING NUCLEIC ACIDS
#27CTLA-4 Binding Molecule and Use Thereof
#28ANTI-PDL1 ANTIBODIES AND METHODS OF USE
#29ALBUMIN BINDING PROTEINS AND METHODS OF USE
#30DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#31SARBECOVIRUS SPIKE S2 SUBUNIT BINDERS
#32NK ENGAGER MOLECULES AND METHODS OF USE THEREOF
#33Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
#34SINGLE DOMAIN ANTIBODIES FOR THE DETECTION OF PLASMIN-CLEAVED VWF
#35ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS
#36POLYNUCLEOTIDES ENCODING, AND METHOD OF MAKING, A POLYPEPTIDE COMPRISING A VHH WHICH BINDS INTERLEUKIN- RECEPTOR (IL-7R)
#37RECOMBINANT POLYPEPTIDES COMPRISING SINGLE-DOMAIN ANTIBODIES TARGETING HERV-K SUBTYPE HML-2
#38Camelid Antibodies for Use in Therapy and Diagnosis
#39Anti-CD98hc VNARs for Crossing the Blood Brain Barrier and Type IV VNAR Libraries
#40Cation-Independent Mannose-6-Phosphate Receptor Binders
#41SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST OPIOIDS
#42CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF
#43BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF
#44TREATMENT FOR ACUTE MYELOID LEUKEMIA WITH ANTI-CD70 ANTIBODIES
#45P97-BASE PROTAC ANTIBODY CONJUGATES AND METHODS OF USE
#46DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
#47BINDING MOLECULES SPECIFIC TO HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
#48CEACAM5-DEPENDENT 4-1BB-AGONISTIC BISPECIFIC ANTIBODIES
#49LIGANDS SPECIFIC FOR THE PCPE-1 GLYCOPROTEIN AND USES THEREOF
#50COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING
#51IL27RAlpha BINDING MOLECULES AND METHODS OF USE
#52CAMELID ANTI-SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS ANTIBODIES
#53Binding Domains Directed Against GPCR:G Protein Complexes and Uses Derived Thereof
#54CAMELID ANTIBODIES AGAINST ACTIVATED PROTEIN C AND USES THEREOF
#55IL10 RECEPTOR BINDING MOLECULES AND METHODS OF USE
#56MULTIVALENT LINKERS USED FOR ANTIBODY LABELING
#57B7-H3 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF
#58VHH ANTIBODY
#59MMP13 BINDING IMMUNOGLOBULINS
#60SARS-CoV-2 BINDING PROTEINS AND METHODS OF USE THEREOF
#61DEVELOPMENT OF NANOBODIES AS FIRST-IN-CLASS INHIBITORS FOR THE DENEDDYLATING ENZYME NEDP1
#62COMPOSITIONS AND METHODS USEFUL IN PROMOTING MILK PRODUCTION
#63SINGLE-DOMAIN ANTIBODY AGAINST SVA AND USES THEREOF
#64ANTIBODY TARGETING CD3, MULTISPECIFIC ANTIBODY, AND USES THEREOF
#65ALPHA-SYNUCLEIN SINGLE DOMAIN ANTIBODIES
#66METHOD OF PREPARING PH-DEPENDENT ANTIBODIES
#67TNFR2 BINDING MOLECULE AND USE THEREOF
#68MODIFYING THE IMMUNE RESPONSE IN PLANTS
#69ANTI-BCMA NANOBODY AND USE THEREOF
#70IL2RB/IL2G SYNTHETIC CYTOKINES
#71MULTIFUNCTIONAL MOLECULES COMPRISING G6B BINDER AND/OR CD34 BINDER AND USES THEREOF
#72VEGF-BINDING PROTEIN AND USE THEREOF
#73Camelid/Llama Nanobodies to Target WNT16B as a Chemotherapy Option for Cancer Treatment
#74ANTIGEN-BINDING POLYPEPTIDES AGAINST CD73
#75SINGLE-DOMAIN 4-1BB ANTIBODIES
#76PROTEIN-BASED CONJUGATION CARRIERS
#77Polypeptides That Bind to von Willebrand Factor (VWF) A1 Domain or an Autoinhibitory Module, Variants, and Uses Thereof
#78CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
#79MULTISPECIFIC ANTIBODIES AND USES THEREOF
#80SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES
#81IMMUNOMODULATING TRANSGENIC PLANTS AND RELATED METHODS
#82HUMANIZED ANTIBODY INHIBITORS FOR CATHEPSIN S
#83Multivalent and Multispecific DR5-Binding Fusion Proteins
#84IL23R BINDING MOLECULES AND METHODS OF USE
#85D3-BINDING MOLECULES AND USES THEREOF
#86Tetanus prophylaxis
#87BISPECIFIC ANTIGEN BINDING CONSTRUCT
#88SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF
#89LUMINESCENT BASED ANTIGEN ASSAY
#90ANTIGEN-BINDING POLYPEPTIDES AGAINST CD39
#91COMBINED ANTAGONISTS AGAINST IL-5/IL-5R AND EITHER IL-4/IL-4R OR IL-13/IL-13R
#92AFFINITY MOLECULES AND METHODS FOR THEIR USE
#93ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES
#94ANTIGEN-BINDING POLYPEPTIDES DIRECTED AGAINST CD38
#95PROTEIN SCREENING AND DETECTION METHOD
#96B CELL MATURATION ANTIGEN BINDING PROTEINS
#97LABELING OF ANTIBODIES
#98ANTIGEN BINDING PROTEIN AND USE THEREOF
#99COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
#100ANTI-CD72 NANOBODIES FOR IMMUNOTHERAPY
#101CEACAM5-dependent 4-1BB-agonistic bispecific antibodies
#102SERUM ALBUMIN BINDERS
#103MATERIALS AND METHODS FOR BINDING SIGLEC-3/CD33
#104VHH-BASED NKP30 BINDERS
#105CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#106CD28 SHEDDING BLOCKING AGENTS
#107ANTIBODIES TARGETING AFP PEPTIDE/MHC COMPLEXES AND USES THEREOF
#108ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES
#109GENETICALLY-MODIFIED SACCHAROMYCES YEAST STRAINS AS PREVENTATIVE AND THERAPEUTIC AGENTS
#110ANTIBODIES THAT BIND SARS-COV-2 SPIKE PROTEIN
#111KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME
#112DPEP-1 BINDING AGENTS AND METHODS OF USE
#113LLAMA-DERIVED NANOBODIES BINDING THE SPIKE PROTEIN OF NOVEL CORONAVIRUS SARS-COV-2 WITH NEUTRALIZING ACTIVITY AND APPLICATION THEREOF
#114Antigen-Binding Domain
#115BINDING MOLECULE AGAINST DLL3 AND USE THEREOF
#116GALECTIN-1-SPECIFIC MONOVALENT ANTIBODIES AND USES THEREOF
#117SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
#118TARGETING T REGULATORY CELLS TO ISLET CELLS TO STALL OR REVERSE TYPE 1 DIABETES
#119Compositions and methods related to IL27 receptor binding
#120IMMUNOMODULATING TRANSGENIC PLANTS AND RELATED METHODS
#121T CELL RECRUITING POLYPEPTIDES CAPABLE OF BINDING CD123 AND TCR ALPHA/BETA
#122GP130 Binding Molecules and Methods of Use
#123MESOTHELIN BINDING MOLECULE AND APPLICATION THEREOF
#124CAMELID ANTI-SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS ANTIBODIES
#125AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
#126IL12RB1-BINDING MOLECULES AND METHODS OF USE
#127ANTIGEN-BINDING DOMAIN, AND POLYPEPTIDE INCLUDING CONVEYING SECTION
#128MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS
#129METHODS OF TREATING AN OCULAR DISEASE OR DISORDER
#130SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
#131TARGETING T REGULATORY CELLS TO ISLET CELLS TO STALL OR REVERSE TYPE 1 DIABETES
#132NOVEL AFFINITY CONSTRUCTS AND METHODS FOR THEIR USE
#133MESOTHELIN BINDING PROTEINS
#134ENGINEERING BACILLUS SUBTILIS AS A VERSATILE AND STABLE PLATFORM FOR PRODUCTION OF NANOBODIES
#135B7-H3 NANOBODY, PREPARATION METHOD AND USE THEREOF
#136AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA
#137AN ANTIBODY FRAGMENT BASED ANTIMICROBIAL CONJUGATE SELECTIVELY TARGETING PSEUDOMONAS
#138VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF
#139ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHY
#140GUCY2C BINDING MOLECULES AND USES THEREOF
#141GPC3 ANTIBODY AND APPLICATION THEREOF
#142PEPTIDE COMPOSITIONS AND METHODS FOR ANTI-CD3 BINDING DOMAINS
#143POLYMER FOR PURIFICATION OF BIOMOLECULES
#144ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
#145CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#146STRUCTURE, METHOD FOR PRODUCING SAME, ADSORBENT IN WHICH SAME IS USED, AND METHOD FOR PURIFYING BIOPARTICLES
#147ANTI-IgG NANOBODIES
#148CD70 combination therapy
#149EXPRESSION AND MANUFACTURING OF PROTEIN THERAPEUTICS IN SPIRULINA
#150COMPOSITIONS AND METHODS FOR RAPID PRODUCTION OF VERSATILE SINGLE DOMAIN ANTIBODY REPERTOIRES
#151ANTI-CD22 NANO ANTIBODY AND USE THEREOF
#152CALRETICULIN NANOBODIES
#153IMMUNE CHECKPOINT INHIBITOR
#154NANOBODIES WITH SPECIFIC AFFINITY FOR VOLTAGE GATED SODIUM CHANNELS
#155MULTISPECIFIC ANTIBODIES AND USES THEREOF
#156ANTI-IL5 NANOANTIBODY AND USE THEREOF
#157SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF
#158SINGLE DOMAIN ANTIBODIES THAT TARGET SARS-COV-2
#159Materials And Methods For Binding Siglec-3/CD33
#160Materials And Methods For Binding Siglec-3/CD33
#161BINDING PROTEINS AND ANTIGEN BINDING FRAGMENTS THEREOF THAT BIND ABETA
#162NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT
#163NOVEL ANTI-PD-1 ANTIBODIES
#164METHODS FOR DE-CLOAKING CANCER FROM THE IMMUNE SYSTEM THROUGH DOWNREGULATION OF CANCER-PRODUCED PREGNANCY SPECIFIC GLYCOPROTEIN
#165YEAST-BASED IMMUNOTHERAPY AGAINST CLOSTRIDIUM DIFFICILE INFECTION
#166IL10 receptor binding molecules and methods of use
#167AGGRECAN BINDING IMMUNOGLOBULINS
#168CELL-FREE ANTIBODY ENGINEERING PLATFORM AND NEUTRALIZING ANTIBODIES FOR SARS-COV-2
#169IL10RB binding molecules and encoding nucleic acids
#170IL27RAlpha binding molecules and methods of use
#171Anti-fungal polypeptides
#172Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
#173IL12 receptor synthetic cytokines and methods of use
#174IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE
#175IL10Ra/IL2Ry SYNTHETIC CYTOKINES
#176IL2RB/IL2RG SYNTHETIC CYTOKINES
#177IL10RA binding molecules and methods of use
#178IL2RG binding molecules and methods of use
#179IFNGR binding synthetic cytokines and methods of use
#180TRANSGENIC ANIMALS EXPRESSING HEAVY CHAIN ANTIBODIES
#181NOVEL CELL LINE
#182ANTIBODIES TO CD70
#183SINGLE VARIABLE DOMAIN AND ANTIGEN BINDING MOLECULE BINDING BCMA
#184Materials And Methods For Binding Siglec-3/CD33
#185TRANSGENIC PLANTS EXPRESSING A VARIABLE DOMAIN OF HEAVY-CHAIN ANTIBODY (VHH) THAT BINDS TO A SPHINGOLIPID OF A FUNGUS
#186HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
#187TARGETED MODIFIED IL-1 FAMILY MEMBERS
#188ANTI-TRANSFERRIN EXTRACELLULAR VESICLES
#189CYSTEINE LINKED NANOBODY DIMERS
#190TAU SINGLE DOMAIN ANTIBODIES
#191INDUCTION OF CONCURRENT PULMONARY IMMUNE MODULATION AND REGENERATION BY PROTEIN MEDIATED CONJUGATION OF IMMUNE REGULATORY CELLS WITH ENDOGENOUS PROGENITOR CELLS
#192CD8 BINDING AGENTS AND USES THEREOF
#193CLAUDIN18.2 BINDING MOIETIES AND USES THEREOF
#194TAU BINDING COMPOUNDS
#195RED LIGHT-CONTROLLED PROTEIN DIMERIZATION SYSTEMS
#196LUCIFERASE LINKED IMMUNOSORBENT ASSAY
#197SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY
#198CD8 BINDING AGENTS
#199ANTI-FUNGAL POLYPEPTIDES
#200THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
#201ANTI-IL-22R ANTIBODIES
#202Glycosylated Single Chain Immunoglobulin Domains
#203SERUM ALBUMIN BINDERS
#204Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R)
#205Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
#206USE OF MMP INHIBITION
#207NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
#208Sequence-Based High Throughput Method Generating Camelids Antibodies to Cover Broad Epitopes with High-Resolution
#209Methods for inhibiting tumor growth or treating cancer by administering an immunoglobulin single variable domain that binds glucocorticoid-induced TNFR family-related receptor (GITR)
#210ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS
#211SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS
#212INSECT CONTROL NANOBODIES AND USES THEREOF
#213Polypeptides comprising immunoglobulin chain variable domains which bind to interleukin-6 receptor (IL-6R) and methods of use thereof to treat autoimmune and inflammatory diseases
#214HIGH AFFINITY NANOBODIES TARGETING B7-H3 (CD276) FOR TREATING MULTIPLE SOLID TUMORS
#215SERUM ALBUMIN BINDERS
#216SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
#217VHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases
#218NK ENGAGER COMPOUNDS THAT BIND VIRAL ANTIGENS AND METHODS OF USE
#219Polypeptides antagonizing Wnt signaling in tumor cells
#220CLEC9A BINDING AGENTS
#221IMMUNOGLOBULIN VARIABLE DOMAINS
#222IMMUNOGLOBULIN VARIABLE DOMAINS
#223MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION
#224RADIOLABELLED ANTIBODY FRAGMENTS FOR USE IN TREATING CANCER
#225A SINGLE-DOMAIN ANTIBODY FOR TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)
#226ANTI-MGLUR5 ANTIBODIES AND USES THEREOF
#227Immunomodulating transgenic plants and related methods
#228SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS
#229ANTIBODIES AND BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER
#230Single domain antibodies binding to tetanus neurotoxin
#231IMMUNOSENSOR
#232Long-Acting Therapeutic Fusion Proteins
#233Method useful in tolerance induction therapy and kits therefore
#234Immunoglobulin variable domains
#235ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#236BISPECIFIC NANOBODIES
#237Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B
#238TRIPLE-CHAIN ANTIBODY, METHOD FOR PREPARATION AND USE THEREOF
#239PROTEASE-ACTIVATING CD45-GATE CAR
#240BCMA chimeric antigen receptor based on single domain antibody and use thereof
#241MONOCLONAL ANTIBODY THAT BINDS SPECIFICALLY TO GITR
#242ALBUMIN BINDING ANTIBODIES AND USE THEREOF
#243TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS
#244Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
#245CD8 BINDING AGENTS
#246Method of preparing pH-dependent antibodies
#247FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES
#248TARGETED DELIVERY OF IMMUNE-MODULATING VHH AND VHH-FUSION PROTEIN
#249SMALL SHEDDING BLOCKING AGENTS
#250Anti-lag-3 antibody polypeptide
#251Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
#252MONOVALENT ANTI-PROPERDIN ANTIBODIES AND ANTIBODY FRAGMENTS
#253Anti-MET antibodies and uses thereof
#254Immunoglobulin variable domains
#255A GENETICALLY MODIFIED LACTOBACILLUS AND USES THEREOF
#256CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
#257PROBIOTIC COMPOSITIONS COMPRISING LACTOBACILLUS REUTERI STRAINS AND METHODS OF USE
#258SIRP1α targeted chimeric proteins and uses thereof
#259Immunoglobulin variable domains
#260TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#261MODULATION OF DENDRITIC CELL LINEAGES
#262NOVEL BISPECIFIC ANTIBODY MOLECULE AND BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO PD-L1 AND LAG-3
#263Protein binding domains stabilizing functional conformational states of GPCRS and uses thereof
#264Immunoglobulins binding human Vγ9Vδ2 T cell receptors
#265CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF
#266Galectin-7-specific monovalent antibodies and uses thereof
#267AGGRECAN BINDING IMMUNOGLOBULINS
#268Antigen-binding domain, and polypeptide including conveying section
#269IL-6 binding molecules
#270Cross species single domain antibodies targeting mesothelin for treating solid tumors
#271Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells
#272PD1 AND/OR LAG3 BINDERS
#273Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
#274COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES
#275Alpha-synuclein single domain antibodies
#276Bispecific binding molecules binding to VEGF and Ang2
#277T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY
#278THERAPEUTIC COMPOUNDS AND METHODS
#279METHOD FOR ENGINEERING IMMUNOGLOBULINS
#280NK engager molecules and methods of use thereof
#281DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#282Bispecific antibodies for use in the treatment of hematological malignancies
#283Anti-PD-1 antibodies
#284Nucleic acids encoding single domain antibodies to chikungunya virus
#285Synthetic single domain antibody
#286METHOD FOR AFFINITY PURIFICATION
#287TRANSGENIC PLANT COMPRISING A POLYNUCLEOTIDE ENCODING A VARIABLE DOMAIN OF HEAVY-CHAIN ANTIBODY
#288MUSCARINIC ACETYLCHOLINE RECEPTOR BINDING AGENTS AND USES THEREOF
#289Antigen-binding polypeptides directed against CD38
#290Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory molecule
#291GARP-TGF-BETA ANTIBODIES
#292Polypeptides
#293Immunoglobulin variable domains
#294Immunoglobulin variable domains
#295ANTIBODIES AGAINST DISEASE CAUSING AGENTS OF POULTRY AND USES THEREOF
#296CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
#297Immunoglobulin variable domains
#298AGROCHEMICAL COMPOSITIONS COMPRISING ANTIBODIES BINDING TO SPHINGOLIPIDS
#299NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF
#300Therapeutic targeting of non-cellular structures